D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis-
![D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis- Structure](https://image.chemsrc.com/caspic/221/105816-06-6.png)
D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis- structure
|
Common Name | D-Phenylalanine, N-[[4-(1-methylethyl)cyclohexyl]carbonyl]-, cis- | ||
|---|---|---|---|---|
| CAS Number | 105816-06-6 | Molecular Weight | 317.42300 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C19H27NO3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
| Name | Nateglinide Related CoMpound C |
|---|
| Molecular Formula | C19H27NO3 |
|---|---|
| Molecular Weight | 317.42300 |
| Exact Mass | 317.19900 |
| PSA | 66.40000 |
| LogP | 3.65180 |
|
Formulation and in vitro evaluation of nateglinide microspheres using HPMC and carbopol-940 polymers by ionic gelation method.
Pak. J. Pharm. Sci. 26(6) , 1229-35, (2013) This study involves the design and characterization of Nateglinide (NAT) microspheres to enhance patient compliance. Ionic gelation technique was used to prepare Nateglinide Microspheres by using rate... |
|
|
II. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: co-milling.
Int. J. Pharm. 454(1) , 568-72, (2013) Nateglinide is an oral antidiabetic agent that should be administered 10-30 min before the meal, but it shows low and pH-dependent solubility that may reduce its oral bioavailability. To improve nateg... |
|
|
I. Technological approaches to improve the dissolution behavior of nateglinide, a lipophilic insoluble drug: nanoparticles and co-mixing.
Int. J. Pharm. 454(1) , 562-7, (2013) Nateglinide is a non-sulphonylurea insulinotropic oral antidiabetic agent. The main problem in formulating an oral dosage form is its low solubility in aqueous media. This problem is particularly crit... |